1-6 of 6
Ellie John
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A post hoc safety analysis of fixed-duration acalabrutinib-venetoclax combinations vs chemoimmunotherapy: Results from the phase 3 AMPLIFY trial

Free
John Seymour, Andrew Aw, Vincent Ribrag, Guillaume Cartron, Arnon Kater, Ki-Seong Eom, Alan Skarbnik, Alessandra Tedeschi, Malgorzata Wach, Jing-Zhou Hou, Arpad Illes, Batul Suterwala, Jiefen Munley, Ellie John, Toshifumi Fujimori, Jennifer Brown
Journal: Blood
Blood (2025) 146 (Supplement 1): 2118.
https://doi.org/10.1182/blood-2025-2118
Published: 2025
Journal Articles

Analysis of predictive factors for POD24 in patients with previously untreated mantle cell lymphoma receiving bendamustine-rituximab with or without acalabrutinib in the phase 3 ECHO trial

Free
Chan Cheah, Stephen Spurgeon, Sung-Soo Yoon, Melina Boutin, Eva Gonzalez Barca, Krimo Bouabdallah, Ellie John, Tatjana Krautloher, Victoria Otero, Brad Kahl
Journal: Blood
Blood (2025) 146 (Supplement 1): 3578.
https://doi.org/10.1182/blood-2025-3578
Published: 2025
Journal Articles

Time to third-line treatment after bendamustine-rituximab with or without acalabrutinib in patients with previously untreated mantle cell lymphoma: Updated analysis of the phase 3 ECHO trial after 50 months of follow-up

Free
Michael Wang, Jonas Paludo, João Samuel de Holanda Farias, Diego Villa, Cecily Forsyth, Ellie John, Menglu Che, Harneet Arora, Craig Delury, Victoria Otero, Yuqin Song
Journal: Blood
Blood (2025) 146 (Supplement 1): 885.
https://doi.org/10.1182/blood-2025-885
Published: 2025
Journal Articles

Impact of prognostic mutations on outcomes with fixed-duration acalabrutinib-venetoclax combinations versus chemoimmunotherapy: An exploratory analysis from AMPLIFY

Free
Paolo Ghia, Barbara Eichhorst, Tomasz Wrobel, Inci Alacacıoğlu, Ana Rita da Fonseca, Dennis Carney, Guillaume Cartron, Alina Gerrie, Don Stevens, Marianne de Borja, Toshifumi Fujimori, Ellie John, L. Alex Liggett, Gary De Jesus, Veerendra Munugalavadla, Jennifer Brown
Journal: Blood
Blood (2025) 146 (Supplement 1): 3898.
https://doi.org/10.1182/blood-2025-3898
Published: 2025
Journal Articles

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

Free
Clinical Trials & Observations
John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (8): 687–699.
https://doi.org/10.1182/blood.2022018818
Published: 2023
Includes: Supplemental data
Journal Articles

Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

Free
John F. Seymour, John C. Byrd, Talha Munir, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Jennifer R. Brown, Anthony R. Mato, Stephan Stilgenbauer, Thomas Fehn, Paulo Andre P. de Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach
Journal: Blood
Blood (2022) 140 (Supplement 1): 7050–7052.
https://doi.org/10.1182/blood-2022-157060
Published: 2022